Due to the development of new PET and CT technologies we have been increasingly able to identify lymph node targets in men with what we previously called biochemical recurrent prostate cancer (PSA only recurrent prostate cancer). As a result, there is increasing interest in treating aggressively these nodal targets.
To assess the value of using metastasis-directed therapy (MDT; salvage node surgery or radiation) researchers retrospectively compared men with node-recurrent prostate cancer receiving MDT with a matched sample of men receiving the current standard of care (androgen-deprivation therapy/ADT).
They determined that MDT was associated with improved cancer-specific survival at five years.
These data provide promising support for the use MDT in lymph node–recurrent prostate cancer. Prostate cancer patients experiencing a lymph node recurrence might benefit from local treatments directed at these lymph nodes. However, the data needs to be evaluated over a longer term of years as well as needing to be confirmed in prospective, randomized studies.
Joel T. Nowak, MA, MSW wrote this Post. Joel is the CEO/Executive Director of Cancer ABCs. He is a Cancer Thriver diagnosed with five primary cancers - Thyroid, Metastatic Prostate, Renal, Melanoma, and the rare cancer Appendiceal cancer.